Interleukin 6 News and Research

RSS

Interleukin-6 (IL-6) is a protein that in humans is encoded by the "IL6" gene. IL-6 is an interleukin that acts as both a pro-inflammatory and anti-inflammatory cytokine. It is secreted by T cells and macrophages to stimulate immune response to trauma, especially burns or other tissue damage leading to inflammation.

Japanese researchers using PET imaging detect the beginnings of atherosclerosis

Using positron emission tomography (PET), the medical isotope 15O-water and cold pressor tests, Japanese researchers were able to detect the beginnings of atherosclerosis - before the disease became clinically evident.

9 Jun 2006

Sunitinib shows promise in treating metastatic renal cell cancer

A new study suggests that sunitinib is a promising agent for treatment of metastatic renal cell cancer, currently a disease without highly effective treatment options, according to an article in the June 7 issue of the Journal of the American Medical Association.

7 Jun 2006

Circulating tumor cells in the bone marrow of patients with metastatic renal cell carcinoma may be prognostic of outcome

Circulating tumor cells in the blood and bone marrow have been examined in a variety of malignancies, including colorectal, breast, and head & neck cancers, to determine their prognostic significance.

8 May 2006

Therapeutic gene suspected to cause cancer

One of the few gene therapy studies that had ever been successful was terminated in 2003, because several of the treated children had developed leukemia.

3 May 2006

Inflammation markers identify fatigue in breast cancer survivors

Researchers at the University of California, Los Angeles have defined conditions associated with disabling fatigue that persists for years in almost a third of breast cancer survivors, according to a study in the May 1 issue of Clinical Cancer Research.

3 May 2006

New insights into how anti-rejection drug daclizumab (Zenapax) helps MS patients

A research team led by the University of Cincinnati's Bibiana Bielekova, MD, report new insights into the role of the MS drug daclizumab (Zenapax) in the Proceedings of the National Academy of Sciences.

11 Apr 2006

Role of hepatic STAT3 in brain-insulin action on hepatic glucose production

New research in Cell Metabolism identifies a key player in the body's ability to respond to insulin action in the brain by ratcheting down the export of blood sugar from the liver.

6 Apr 2006

Natural killer cells and antibody-based immune function

A new drug may boost the effectiveness of a widely used treatment for patients with non-Hodgkin lymphoma (NHL), while simultaneously overcoming drug resistance in those patients.

4 Apr 2006

Immune system protein LL-37 critical in controlling replication of vaccinia virus

Scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), have identified a defect in the immune response of people with the skin condition atopic dermatitis that puts them at risk of developing serious complications following smallpox vaccination.

23 Mar 2006

Potential therapeutic targets against serious side effects of smallpox vaccine

Smallpox is considered a potential terrorist weapon, but millions of people in the United States are currently advised not to get a vaccine to the disease because they are susceptible to developing a severe adverse reaction.

23 Mar 2006

Therapy for metastatic renal cell carcinoma remains inadequate

The recent FDA approvals of the tyrosine kinase inhibitors sorafenib and sunitinib based on their activity in metastatic renal cell carcinoma have excited the medical oncology community

9 Mar 2006

Is there any role for thalidomide as a monotherapy in the management of metastatic renal cell carcinoma?

Thalidomide remains an enigma in the treatment of metastatic renal cell carcinoma (RCC). Initial clinical trials suggested a benefit, but more recently, subsequent randomized trials studying thalidomide in combination with other agents such as interferon have demonstrated no added benefit.

8 Mar 2006

Attaching new cytokine to neural stem cells derived from bone marrow kills brain tumor cells

Attaching a recently discovered cytokine to neural stem cells derived from bone marrow, researchers at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Institute have developed a tool to track and kill malignant brain tumor cells and provide long-term protection against their return.

1 Mar 2006

Selective T cell stimulation could help improve treatment of autoimmune disease and cancer

The findings could also be significant for developing new ways to help patients with autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, or juvenile diabetes.

23 Feb 2006

Interleukin-15 encourages CD8+ T cells to proliferate and reduces their tolerance to tumor antigens

Certain types of white blood cells assist the body in destroying cancerous tumors. Among these are CD8+ T cells. The T is for thymus, the gland near the base of the throat that both raises up and weeds out blood cells involved in immune responses.

20 Feb 2006

Predicting risk of coronary artery disease

The extent of anatomic coronary artery disease, along with age and the presence of diabetes, is a strong predictor of subsequent death due to any cause and due to coronary artery disease (CAD).

16 Feb 2006

Two-drug treatment could help asthma and chronic bronchitis sufferers

Current treatments for asthma and chronic bronchitis aren't able to address the ultimate source of the problem--they can only alleviate symptoms.

7 Feb 2006

Herceptin may work better when it is followed by injections of interleukin

A new study suggests that antibody-based cancer drugs might help patients more if they are given with substances that stimulate the immune system.

5 Jan 2006

Extremely infectious pneumonia-like disease slips through body's immune system

A new study found that an extremely infectious pneumonia-like disease in humans slips through the immune system's usual defense mechanisms.

21 Dec 2005

The role of genes in the development of non-Hodgkin's lymphomas

An international consortium of epidemilogists - including Dr. Alexandra Nieters and Professor Nikolaus Becker of the Clinical Epidemiology Division of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) - has conducted the first ever investigation of genetic factors in the development of non-Hodgkin’s lymphoma (NHL) in a study called InterLymph.

15 Dec 2005